Crinetics Pharmaceuticals, Inc.
CRNXHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeCrinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and. The company carries a $3.75B market cap, placing it firmly in the mid-cap category. The company's lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in a Phase 3 clinical trial for the treatment of acromegaly and carcinoid syndrome associated with neuroendocrine tumors.
Market Cap
$3.75B
Beta
0.28
P/E (TTM)
—
P/E (Fwd)
-8.45
EPS (TTM)
$-5.14
EPS (Fwd)
$-4.21
ROE
-39.2%
ROA
-24.7%
Cash
$1.29B
Total Debt
$47.9M
Free CF
-$242.1M
52W Change
11.5%
Annual Financials
Cash vs Debt
The balance sheet looks solid with $1.29B in cash comfortably exceeding the $47.9M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. The company is burning cash, with free cash flow at -$242.1M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -39.2%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has been uneven over recent years, ranging from $4.7M to $7.7M.
With a beta below 0.7, Crinetics Pharmaceuticals, Inc. typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Crinetics Pharmaceuticals, Inc. and its sector.